Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Mayne Pharma (ASX:MYX) share price crashes 17% on FDA outcome

The Mayne Pharma Group Ltd (ASX: MYX) share price crashed 17% on Tuesday on negative news received from the FDA. Is this a buying opportunity for Mayne shares?

The Mayne Pharma Group Ltd (ASX: MYX) share price crashed 17% on Tuesday on negative news received from the US Food and Drug Administration (FDA).

Mayne Pharma develops, manufactures and markets branded and generic pharmaceutical products globally.

Source: Rask Media MYX 1-year share price chart

What caused investors to dump their MYX shares?

Yesterday, Mayne Pharma revealed it had received a complete response letter from the FDA regarding its application for a generic version of Nuvaring – one of the most popular contraceptive products sold in the US.

Mayne Pharma CEO Scott Richards said, “We are confident we can address the issues raised in the letter in a timely manner. Pleasingly, the FDA has indicated that Mayne Pharma and its development partner Mithra have an acceptable manufacturing process for generic NUVARING”.

Scott confirmed that if approved, the generic Nuvaring product has a total addressable market of US$920 million. Based on yesterday’s crash in the Mayne Pharma share price, it is clear investors were factoring in a high chance of FDA approval.

Mayne’s product portfolio

You would not know it from watching Mayne’s share price, but the generic Nuvaring product is not its only product.

In July 2016, Mayne Pharma paid US$652 million (AUD$911.5 million) for 42 generic drugs from Teva Pharmaceutical Industries. Of these, 37 products were approved by the FDA, with the remaining 5 pending approval.

The market will be closely tracking the company’s products pending FDA approval, so we could expect to see similar volatility in the Mayne share price going forward.

Are Mayne shares a buy?

After Tuesday’s share price collapse, Mayne Pharma has a market capitalisation of just $529 million. This is significantly less than what Mayne paid for the portfolio of generic drugs from Teva just 4 years ago.

In my view, if any of Mayne’s pipeline products gain FDA approval, today’s share price will look cheap. That said, I would like to gain a better understanding of Mayne’s products before buying in.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned
Skip to content